Trump reaches Regeneron deal, completing most-favored-nation pricing push with 17 drugmakers

President Donald Trump announced a deal with Regeneron to bring most-favored-nation drug pricing to state Medicaid programs, marking the 17th agreement his administration has struck with a major pharmaceutical company since last fall. Trump made the announcement from the Oval Office, flanked by Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz, and Commerce Secretary Howard Lutnick, along with top Regeneron executives.

The deal caps a campaign that began with Pfizer on September 30 and has now reached every major drugmaker the administration targeted. Under the agreement, Regeneron's cholesterol drug Praluent will drop from $537 to $225 when purchased through the TrumpRx website, a more than 58 percent cut on a single product.

Trump framed the milestone in blunt terms during his Oval Office remarks:

"With this announcement, 17 of the world's largest pharmaceutical companies, representing 80 percent of the branded drug market, have now agreed to sell their drugs to American patients at the lowest prices anywhere in the world."

That is a staggering claim. And whether it holds up in full will depend on details still emerging. But the sheer pace of these agreements, 17 deals in roughly seven months, represents the kind of direct, company-by-company pressure that Washington rarely musters on any industry, let alone one as politically protected as Big Pharma.

What the Regeneron agreement covers

A White House fact sheet laid out the core terms. The agreement brings state Medicaid programs access to most-favored-nation pricing on new Regeneron drugs. That means Americans covered by Medicaid would pay prices in line with what other wealthy nations pay, rather than the inflated rates that have defined the U.S. market for decades.

The fact sheet also stated that the deal prevents other countries from using "price controls to freeride on American innovation by guaranteeing MFN prices on all new innovative medicines Regeneron brings to market." In plain English: foreign governments have long set artificially low prices for drugs developed largely on the back of American research investment. This deal aims to close that gap from the American side.

There is a repatriation component as well. The White House said the agreement "requires Regeneron to repatriate increased foreign revenue on existing products that Regeneron realizes as a result of the President's strong America First U.S. trade policies for the benefit of American patients." The administration is tying trade leverage directly to pharma pricing, a move previous administrations talked about but never executed at this scale.

The broader pattern of wins for Trump's agenda has extended well beyond drug pricing. In a separate arena, a D.C. Circuit ruling recently rebuked a federal judge who had pressed a contempt probe over administration deportation flights, underscoring the judiciary's limits in blocking executive action.

The full roster of deals

Regeneron is the last name on a list that now includes Pfizer, AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, and AbbVie. Together, Trump said, these 17 companies represent 80 percent of the branded drug market.

Newsmax reported that Regeneron was the final company among the 17 firms Trump targeted last July, and that the deal covers all of Regeneron's current and future drugs on Medicaid. Newsmax also noted a reported $27 billion U.S. investment commitment from Regeneron, though some details of the pricing agreements have drawn scrutiny for remaining undisclosed.

The scale matters. For years, Americans have paid the highest drug prices in the developed world, not because our drugs are better, but because our system lacked the leverage or the will to demand parity. Other nations used government price controls. The United States relied on a patchwork of insurance negotiations, pharmacy benefit managers, and rebate schemes that obscured real costs and enriched middlemen.

Trump's approach bypassed that entire structure. He went straight to the manufacturers.

Meanwhile, Democratic efforts to undermine the president's broader agenda have continued to stall. Democratic lawmakers recently conceded that their impeachment push has no realistic path to success, a tacit admission that the political ground has shifted.

How the TrumpRx website fits in

A key mechanism in these deals is the TrumpRx website, which the administration has positioned as a direct-to-consumer portal for discounted medications. The Praluent price drop, from $537 to $225, runs through this site. National Review noted that the administration plans to use TrumpRx.gov to direct patients to manufacturers' direct-buy websites, and that drugmakers also agreed to sell most products to state Medicaid programs at prices offered in other wealthy countries.

National Review's John R. Puri also observed that the practical savings for most insured Americans may be limited, since many patients already receive drugs through employer-sponsored plans or Medicare Part D, where negotiated prices differ from list prices. That is a fair caveat. But for Medicaid patients, low-income Americans who often face the starkest choices between medication and other necessities, the pricing shift could be substantial.

The administration clearly sees Medicaid as the pressure point. By securing most-favored-nation pricing for state Medicaid programs specifically, the White House is targeting the population least able to absorb inflated costs and most dependent on government programs that have historically overpaid.

Trump's own assessment

Trump did not understate the significance. Speaking from the Oval Office, he offered a characteristically direct assessment:

"This will result in the largest drop in prescription drug prices in the history of the United States of America. I mean, it should be front page news, but it won't be. It'll be back on page 19, but the people get it. That's why we're in the Oval Office, I guess."

He is not wrong about the coverage gap. A sitting president completing 17 separate pricing agreements with the largest pharmaceutical companies in the world, covering 80 percent of the branded drug market, would, in any normal media environment, dominate the news cycle. Instead, it has been treated as a secondary story at best.

The Washington Examiner reported that the White House calendar listed the event as a "Health Care Affordability Event," and that press secretary Karoline Leavitt described it as the latest in the administration's string of pharmaceutical pricing deals. Regeneron joins Eli Lilly, Merck, Pfizer, and the rest in making formal agreements with the administration.

Trump also introduced the deal with a personal note on Regeneron's reputation:

"Today, I'm thrilled to announce that one of the most respected pharmaceutical companies anywhere in the world, frankly, I know it very well, is Regeneron, and it's agreed to offer their prescription medications at heavily discounted most-favored-nation prices."

What remains unanswered

Several questions linger. The full terms of the Regeneron agreement beyond the excerpts cited from the White House fact sheet have not been publicly released. It is unclear which specific new Regeneron drugs are covered by the Medicaid pricing access, and whether the agreement extends beyond Medicaid to other patient populations. The enforcement mechanisms, what happens if Regeneron or any of the 17 companies fail to honor the terms, remain unspecified in public documents.

These are not trivial gaps. The history of government-industry deals is littered with agreements that looked strong on announcement day and eroded quietly over time. Transparency on the full terms will matter.

The administration's broader posture, however, suggests it is willing to use trade policy as a backstop. The White House fact sheet explicitly tied the repatriation requirement to "the President's strong America First U.S. trade policies." That linkage, drug pricing backed by tariff leverage, is new territory. It is also the kind of structural pressure that previous administrations, both Republican and Democrat, declined to apply.

In a separate but telling development, a federal appeals court recently cleared construction of the White House ballroom to continue, another instance of the administration prevailing against legal challenges to its agenda.

The bigger picture

For decades, drug pricing has been one of Washington's most reliable broken promises. Presidents from both parties have pledged to bring costs down. Congress has held hearings. Task forces have issued reports. And Americans have continued to pay more than patients in Canada, Germany, Japan, and virtually every other developed nation.

What Trump has done, agree by agree, company by company, starting with Pfizer last September and ending with Regeneron now, is bypass the legislative gridlock entirely. He used executive leverage, trade policy, and direct negotiation to extract concessions that Congress never delivered through legislation.

Whether the savings reach every American household remains to be seen. The Medicaid focus is clear. The TrumpRx website offers a direct channel. But the broader insurance market, with its layers of middlemen and opaque rebate structures, may take longer to feel the effects.

The administration has also faced legal resistance on multiple fronts beyond health care, though courts have increasingly sided with the White House. A federal judge recently tossed an injunction that had attempted to block a high-profile White House construction project, part of a pattern of judicial setbacks for those challenging executive authority.

Still, the drug-pricing push stands on its own merits. Seventeen companies. Eighty percent of the branded market. A direct pricing portal. Most-favored-nation terms for Medicaid. And a repatriation clause that ties pharma revenue to American patients. That is not a press release. That is a record.

Washington spent years telling Americans that lower drug prices were too complicated to deliver. It turns out they just required someone willing to pick up the phone and make the deal.